Time filter

Source Type

Malvern, PA, United States

TetraLogic Pharmaceuticals | Date: 2013-11-08

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

TetraLogic Pharmaceuticals | Date: 2014-07-21

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language

TetraLogic Pharmaceuticals | Date: 2013-08-01

A combination therapy comprising administration of a Smac mimetic and GM-CSF.

TetraLogic Pharmaceuticals | Date: 2014-04-07

A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.

TetraLogic Pharmaceuticals | Date: 2014-07-16

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K

Discover hidden collaborations